ArticleAdvances in therapy2024

Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study.

Jianping Xiong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.